Cam Gallagher - 05 Oct 2022 Form 4 Insider Report for Zentalis Pharmaceuticals, Inc. (ZNTL)

Role
President, Director
Signature
By: /s/ Melissa B. Epperly, attorney-in-fact for Cam S. Gallagher
Issuer symbol
ZNTL
Transactions as of
05 Oct 2022
Net transactions value
-$505,186
Form type
4
Filing time
07 Oct 2022, 16:40:26 UTC
Previous filing
16 Sep 2022
Next filing
17 Oct 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZNTL Common Stock Sale $153,528 -7,004 -1.6% $21.92 437,381 05 Oct 2022 Direct F1, F2
transaction ZNTL Common Stock Sale $125,478 -5,496 -1.3% $22.83 431,885 05 Oct 2022 Direct F1, F3
transaction ZNTL Common Stock Sale $226,180 -10,000 -2.3% $22.62 421,885 06 Oct 2022 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected pursuant to a plan that complies with Rule 10b5-1 and expires June 5, 2023.
F2 The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $21.43 to $22.42. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $22.47 to $23.17. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $22.20 to $23.11. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.